Castelli Jeff 4

What Happened
Jeff Castelli, Chief Development Officer of Amicus Therapeutics (FOLD), disposed of 427,089 shares of Amicus common stock (318,417 shares + 108,672 RSUs that vested at closing) at $14.50 per share for proceeds of $6,192,791 on 2026-04-27 in connection with the company’s acquisition by BioMarin. In addition, multiple stock options totaling 673,537 underlying shares were cancelled and converted into the right to receive cash based on the merger consideration (payment equal to $14.50 per share minus each option’s exercise price, multiplied by the number of shares). All options were fully vested and vested in connection with the merger.

Key Details

• Transaction date: 2026-04-27 (reported on Form 4 filed 2026-04-27).
• Cash received for common stock/RSUs: 427,089 shares × $14.50 = $6,192,791.
• Options cancelled/converted to cash: 82,644; 107,575; 108,266; 125,462; 99,073; 150,517 (total 673,537 underlying shares). Dollar amounts for option cashouts were not disclosed on the Form 4.
• Each option was fully vested and vested in connection with the merger (footnotes F2–F4).
• Shares owned after the transaction: not specified in the data provided on the filing.
• Reason: Dispositions occurred in connection with the consummation of Amicus’s acquisition by BioMarin (per filing footnotes).
• Filing timeliness: No late filing flag indicated in the provided details.

Context
These actions were merger-related cash-outs: vested RSUs and common shares were paid out at the merger price, and vested stock options were cancelled for a cash payment equal to the excess of the merger price over each option’s exercise price. Such dispositions tied to a company acquisition are routine and reflect transaction mechanics rather than standalone insider selling for personal reasons.